Changes in the activity of connective tissue matrix enzymes in the metabolic syndrome

Archives of Medical Science

Volumn 7, Issue 4, 2011, Pages 634-641

  Mieczkowska, Jolanta ^a   Mosiewicz, Jerzy ^a   Barud, Wojciech ^a   Kwasńiewski, Wojciech ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Atherosclerosis; Cytokines; Metabolic syndrome; Metalloproteinase; Tissue inhibitors of metalloproteinases

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL OXIDASE; FIBRINOGEN; GELATINASE B; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NEUTROPHIL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTERIAL PRESSURE; ARTICLE; BIOLOGICAL ACTIVITY; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOVASCULAR RISK; CATALYSIS; CLINICAL ARTICLE; CONNECTIVE TISSUE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ENZYME ACTIVITY; FEMALE; FIBRINOGEN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; LIPID HYDROLYSIS; LIPID OXIDATION; METABOLIC SYNDROME X; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; WAIST HIP RATIO;

EID: 80052569582     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2011.24133     Document Type: Article

References (35)

1. Watanabe N, Ikeda U. Matrix metalloproteinases and atherosclerosis. Curr Atheroscler Rep 2004; 6: 112-20. (Pubitemid 38914955)
2. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995; 77: 863-8.
3. Shanker J, Kakkar VV. Role of periodontal infection in cardiovascular disease: A current perspective. Arch Med Sci 2009; 5: 125-34.
4. Camejo G, Hurt-Camejo E, Olsson U, Bondjers G. Lipid mediators that modulate the extracellular matrix structure and function in vascular cells. Curr Atheroscler Rep 1999; 1: 142-9.
5. Lemaitre V, O'Byrne TK, Borczuk AC, Okada Y, Tall AR, D'Armiento J. ApoE knockout mice expressing human matrix metalloproteinase-1 in macrophages have less advanced atherosclerosis. J Clin Invest 2001; 107: 1227-34. (Pubitemid 32494539)
6. Kaddah S, Rashed L, Obaia E, Sabry D. A preliminary study: Matrix metalloproteinase expression as an indicator of the hazards of shisha (nargila) smoking. Arch Med Sci 2009; 5: 570-6.
7. Barylski M, Banach M, Mikhailidis DP, Pawlicki L, Kowalski J. Decreased kidney function as a risk factor for cardiovascular events in subjects with metabolic syndrome - A pilot study. Arch Med Sci 2008; 4: 417-23.
8. El Messal M, Beaudeux JL, Drissi A, et al. Elevated serum levels of proinflammatory cytokines and biomarkers of matrix remodeling in never-treated patients with familial hypercholesterolemia. Clin Chim Acta 2006; 366: 185-9. (Pubitemid 43330981)
9. Tayebjee MH, Nadar S, Blann AD, Beevers GD, MacFadyen RJ, Lip GY. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hypertens 2004; 17: 764-9. (Pubitemid 39201090)
10. Ikonomidis JS, Jones JA, Barbour JR, et al. Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with bicuspid or tricuspid aortic valves. J Thorac Cardiovasc Surg 2007; 133: 1028-36. (Pubitemid 46435954)
11. Lee SW, Song KE, Shin DS, et al. Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes. Diabetes Res Clin Pract 2005; 69: 175-9.
12. Jacqueminet S, Ben Abdesselam O, Chapman MJ, et al. Elevated circulating levels of matrix maealloproteinase-9 in type 1 diabetic patients with and without retinopathy. Clin Chim Acta 2006; 367: 103-7.
13. Kangavari S. Smoking increases inflammation and metallo proteinase expression in human carotid atherosclerotic plaques. Cardiovasc Pharmacol Ther 2004; 9: 291-8. (Pubitemid 40130016)
14. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome: http://www.idf.org, 2005.
15. Yamamoto D, Takai S, Jin D, Inagaki S, Tanaka K, Miyazaki M. Molecular mechanism of imidapril for cardiovascular protection via inhibition of MMP-9. J Mol Cell Cardiol 2007; 43: 670-6. (Pubitemid 350166378)
16. Venugopal SK, Devaraj S, Jialal I. Effect of C-reactive protein on vascular cells: Evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens 2005; 14: 33-7. (Pubitemid 40110697)
17. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: A marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23: 168-75. (Pubitemid 36231924)
18. Pasqui AL, Di Renzo M, Bova G, et al. Pro-inflammatory/anti-inflammatory cytokine imbalance in acute coronary syndromes. Clin Exp Med 2006; 6: 38-44.
19. Tziakas DN, Chalikias GK, Hatzinikolaou HI, et al. Antiinflammatory cytokine profile in acute coronary syndromes; behavior of IL-10 in association with serum metalloproteinases and inflammatory cytokines. Int J Cardiol 2003; 92: 169-75. (Pubitemid 37509978)
20. Arai KI, Lee F, Miyajima A, Miyatake S, Arai N, Yokota T. Cytokines: Coordinators of inflammatory response. Ann Rev Inc 1990; 59: 783-836.
21. Mizia-Stec K, Gasior Z, Zahorska-Markiewicz B, et al. Serum tumor necrosis factor-alfa, IL-2 and IL-10 activation in stable angina and acute coronary syndromes. Coron Artery Dis 2003; 14: 431-8. (Pubitemid 37070321)
22. Sabatine MS, Morrow DA, De Lemos JA, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002; 105: 1760-3. (Pubitemid 34408881)
23. Roberts CK, Won D, Pruthi S, et al. Effect of a short-term diet and exercise intervention on oxidative stress, inflammation, MMP-9, and monocyte chemotactic activity in men with metabolic syndrome factors. J Appl Physiol 2006; 100: 1657-65.
24. Goncalves FM, Jacob-Ferreira AL, Gomes VA, et al. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome. Clin Chim Acta 2009; 403: 173-7.
25. Marx N, Froehlich J, Siam L, et al. Antidiabetic PPAR {gamma}-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2003; 23: 283-8. (Pubitemid 36231941)
26. Pawlak K, Pawlak D, Mysliwiec M. Circulating beta-chemokines and matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system in hemodialyzed patients-role of oxidative stress. Cytokine 2005; 31: 18-24. (Pubitemid 40834317)
27. Signorelli SS, Malaponte G, Libra M, Di Pino L, Celotta G, Bevelacqua V. Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripherial arterial disease. Vasc Med 2005; 10: 1-6. (Pubitemid 40667579)
28. Nanni S, Melandri G, Hanemaaijer R, et al. Matrix metalloproteinases in premature coronary atherosclerosis: Influence of inhibitors, inflammation, and genetic polymorphisms. Transl Res 2007; 149: 137-44. (Pubitemid 46275571)
29. Głowińska-Olszewska B, Urban M. Elevated matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in obese children and adolescents. Metabolism 2007; 56: 799-805. (Pubitemid 46734087)
30. Tayebjee MH, Nadar SK, MacFadyen RJ, Lip GY. Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension. Relationship to tissue Doppler indices of diastolic relaxation. Am J Hypertens 2004; 17: 770-4. (Pubitemid 39201091)
31. Derosa G, D'Angelo A, Let C, et al. Matrix metallo proteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium 2006; 13: 227-31. (Pubitemid 44110588)
32. Kato R, Momiyama Y, Ohmori R, Taniguchi H, Nakamura H, Ohsuzu F. Plasma matrix metalloproteinase-8 concentrations are associated with the presence and severity of coronary artery disease. Circ J 2005; 69: 1035-40. (Pubitemid 41603087)
33. Owen CA, Hu Z, Lopez-Otin C, Shapiro SD. Membrane-bound matrix metalloproteinase-8 on activated polymorphonuclear cells is a potent, tissue inhibitor of metalloproteinase-resistant collagenase and serpinase. J Immunol 2004; 172: 7791-803. (Pubitemid 38747647)
34. Momiyama Y, Ohmori R, Tanaka N, et al. High plasma levels of matrix metalloproteinase-8 in patients with unstable angina. Atherosclerosis 2010; 209: 206-10.
35. Wilson WR, Anderton M, Schwalbe EC, et al. Matrix metalloproteinase-8 and -9 are increased at the site of abdominal aortic aneurysm rupture. Circulation 2006; 113: 438-45. (Pubitemid 43803206)